Liver and Bile

J Hepatol. 2023;78(3):501–12

Louvet A, Bourcier V, Archambeaud I, d’Alteroche L, Chaffaut C, Oberti F, Moreno C, Roulot D, Dao T, Moirand R, Duclos-Vallée JC, Goria O, Nguyen-Khac E, Pol S, Carbonell N, Gournay J, Elkrief L, Fouchard-Hubert I, Chevret S, Ganne-Carrié N; CIRRAL group

Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort


Background and aims: The harmful impact of heavy alcohol consumption and recurrence in patients with alcohol-related cirrhosis is long-established, although this is based on old studies. However, the drivers of long-term outcome still need to be clearly investigated. Method: All patients with biopsy-proven compensated alcohol-related cirrhosis included in the CIRRAL cohort (22 centers) were prospectively studied. Prognostic variables of survival and liver event-free survival were assessed using multivariable Cox models with stepwise selection. The prognostic impact of alcohol recurrence during follow-up (computed in glass-years in the same way as pack-years for tobacco) was assessed using a time-dependent covariable.
Results: From 2010 to 2016, 650 patients were included. The median age at baseline was 58.4 years, 67.4% were men and the median body mass index was 27.8 kg/m², 63.8% had a history of liver decompensation, and 70.2% had discontinued alcohol. At 5 years, recurrence occurred in 30.9% of abstinent patients and this risk was higher in patients with a history of drug abuse and in those with shorter alcohol discontinuation times. Median survival was 97 months. Age, alcohol consumption at baseline, platelet count and Child-Pugh score > 5 were associated with overall and liver event-free survival on multivariate analysis. Alcohol consumption of more than 25 glass-years during follow-up was independently associated with lower survival and with a trend toward lower liver event-free survival, with the risk increasing from 1 glass-year, though not significantly. Simon and Makuch plots confirm the benefit of no alcohol consumption (< 1 glass/week) on both outcomes and the dose-dependent impact of alcohol over time.

Conclusion: This prospective study in patients with compensated alcohol-related cirrhosis identifies factors predictive of alcohol recurrence during follow-up and shows that moderate alcohol consumption during follow-up negatively impacts outcomes. Patients with alcohol-related cirrhosis should be advised to completely stop drinking alcohol.

Prof. Dr. A. Louvet, Service des Maladies de l’Appareil Digestif, Hôpital Huriez, Centre Hospitalier Universitaire de Lille, Lille, France,
E-Mail: alexandre.louvet@chru-lille.fr

or

Prof. Dr. N. Ganne-Carrié, Service d’Hépatologie, Hôpital Avicenne, Bobigny, France,
E-Mail: nathalie.ganne@aphp.fr

DOI: DOI: 10.1016/j.jhep.2022.11.013

Back to overview

this could be of interest:

Retreatment with immune checkpoint inhibitors after a severe immune-related hepatitis: Results from a prospective multicenter study

Clin Gastroenterol Hepatol. 2023;21(3):732–40

Incidence and factors predictive of recurrent thrombosis in people with non-cirrhotic portal vein thrombosis

J Hepatol. 2023;78(1):114–22

More articles on the topic